Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array

Hans-Ullrich Völker¹, Michael Weigel², Annette Strehl¹ and Lea Frey³*

Abstract

Background: Conventional parameters including Ki67, hormone receptor and Her2/neu status are used for risk stratification for breast cancer. The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumour invasion and metastasis. Increased concentrations in tumour tissue are associated with more aggressive potential of the disease. Multigene tests provide detailed insights into tumour biology by simultaneously testing several prognostically relevant genes. With OncotypeDX®, a panel of 21 genes is tested by means of quantitative real-time polymerase chain reaction. The purpose of this pilot study was to analyse whether a combination of Ki67 and uPA/PAI-1 supplies indications of the result of the multigene test.

Methods: The results of Ki67, uPA/PAI-1 and OncotypeDX® were analysed in 25 breast carcinomas (luminal type, pT1/2, max pN1a, G2). A statistical and descriptive analysis was performed.

Results: With a proliferation index Ki67 of < 14%, the recurrence score (RS) from the multigene test was on average in the Low risk range, with an intermediate RS usually resulting if Ki67 was > 14%. Not elevated values of uPA and PAI-1 showed a lower rate of proliferation (average 8.5%) than carcinomas with an increase of uPA and/or PAI-1 (average 13.9%); p = 0.054, Student’s t-test. When Ki67 was > 14% and uPA and/or PAI-1 was raised, an intermediate RS resulted. These differences were significant when compared to cases with Ki67 < 14% with non-raised uPA/PAI-1 (p < 0.03, Student’s t-test). Without taking into account the proliferative activity, an intermediate RS was also verifiable if both uPA and PAI-1 showed raised values.

Conclusion: A combination of the values Ki67 and uPA/PAI-1 tended to depict the RS to be expected. From this it can be deduced that an appropriate analysis of this parameter combination may be undertaken before the multigene test in routine clinical practice. The increasing cost pressure makes it necessary to base the implementation of a multigene test on ancillary variables and to potentially leave it out if not required in the event of a certain constellation of results (Ki67 raised, uPA and PAI-1 raised).

Keywords: Breast cancer, uPA, PAI-1, Multigene-array, OncotypeDX®

* Correspondence: lea.frey@uni-wuerzburg.de
³Institute for Pathology, University of Wuerzburg, Josef-Schneider-Str. 2, D-97080 Wuerzburg, Germany

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The risk stratification for breast carcinoma takes into account conventional parameters such as age at onset, menopausal status, tumour size and extension, histological grading and subtype, the assessment of vascular or lymphatic invasion, lympho-nodal status, resection margins and distant metastasis. The determination of the proliferative activity (Ki67) and of the hormone receptor and Her2/neu status are indispensable for prognosis and prediction.

Supplementary analyses of tumour tissue can make the classification more precise. This is especially important in the case of node-negative or minimally positive (max. pN1a) luminal-type carcinomas, because it is in this tumour group that difficulties arise most frequently in making the decision for or against adjuvant chemotherapy.

The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1), as elements of the urokinase plasminogen activator system, are part of the fibrinolytic system [1]. The zymogen plasminogen is converted by uPA into its active, protein-activating and proteolytic form (plasmin) [2]. PAI-1 plays a role in the regulation of the proteolytic activity of uPA [3]. It does not only act as an inhibitor, but also participates in numerous other processes such as cell adhesion and migration, angiogenesis, signal transduction and apoptosis [4, 5]. uPA and PAI-1 thus play an important role in tumour invasion and metastasis through an interaction with components of the basal membrane, the extracellular matrix and by local proteolysis [6–9].

Increased concentrations of uPA and/or PAI-1 in the tumour tissue of breast carcinomas are associated with a more aggressive progression of the disease, an increased risk of relapse and lower survival rates [10, 11]. Several studies have proved a prognostic significance independent of clinical and histopathological criteria [12–14]. uPA/PAI-1 testing has achieved the level of evidence 1a and has been incorporated into the recommendations of the German Working Group for Gynaecological Oncology (http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinien-nempfehlungen/mamma; accessed June 4th 2018). This examination is recommended for lymphonodal non-metastasized and Her2/neu-negative breast carcinoma of intermediate grade (G2). In the case of a high protein level of uPA and/or PAI-1 patients could benefit from adjuvant chemotherapy [11].

Various established multigene tests (e.g. OncotypeDX*, MammaPrint*, EndoPredict®, Prosigna®-Assay) supply detailed insights into tumour biology by simultaneously testing several genes that are relevant to prognosis. OncotypeDX* is a 21-gene assay available in Europe since 2009. The standardized and quality-controlled analysis is carried out in a central laboratory in the USA using quantitative real-time polymerase chain reaction (qRT-PCR). A panel of 21 genes is examined, 16 of which are cancer-associated genes as well as five reference genes. The result is used to calculate the numerical recurrence score (RS), which reflects a defined risk of relapse within 10 years from the point of diagnosis. Three risk groups exist for clinical validation: low risk (RS < 18), intermediate risk (RS 18–30) and high risk (RS ≥ 31). The prognostic importance of these groups has been shown by various studies [15–19]. For patients with high risk tumours adjuvant chemotherapy has been proven to be useful [20].

However, additional tests also increase the costs of the diagnostic process considerably, and these charges are then not always assumed by German health insurance schemes. The increasing cost pressure represents a substantial problem in clinical practice; responsibilities towards the patient on the one hand and towards the cost bearers on the other hand are often irreconcilable.

Although the prognostic value of common testing procedures is well described in current literature, a correlation of the individual tests amongst each other with an assessment of costs and benefits has not to our knowledge been examined in the researchable literature.

In this initial pilot study, derived from routine clinical work, the intention is to analyse whether the ELISA test for the protein levels of uPA and PAI-1, carried out in addition to conventional histopathological parameters, is similarly suitable for the assessment of prognosis as a multigene test, for which OncotypeDX* has here been selected as an example.

Methods

Between 2013 and 2016, 954 breast carcinomas were presented and discussed in the interdisciplinary tumour conference of the Breast Cancer Centre at Leopoldina Krankenhaus der Stadt Schweinfurt GmbH (Leopoldina Hospital of the City of Schweinfurt). Male breast carcinomas were excluded. All epidemiological and clinical data of the patients were available as well as the complete post-operative histopathological tumour diagnostics (especially stage, hormone receptor status, Her2/neu status, Ki67). The data set was completely anonymized so that connections to individual cases, particularly patient names and core data, are no longer possible.

Immunohistochemical parameters were determined in a fully-automated device (BondMax, Leica) with a standardized test-kit (Leica).

The commercially available antibody clone 1D5 was used for the oestrogen receptor stain (ER), and the clone PgR63 (both DAKO®) for the progesterone receptor stain (PR). The immunoreactive score (IRS) was calculated using the method according to Remmele and Stegner, in order to determine the hormone receptor status. This consists of the percentage of positively stained tumour cells and the stain intensity. A score of 0 counts as
negative, 1–3 as weakly positive, 4–6 as moderately positive and 8–12 as strongly positive. The Pathology Department of the Leopoldina Krankenhaus Schweinfurt successfully passed the relevant yearly external quality assurance tests (QuIP®) each year within the survey period.

The test for Her2/neu was performed immunohistochemically (clone c-erbB-2, DAKO), and supplemented with a FISH analysis where the result was not clear. The immunohistochemical stains were evaluated in adherence to guidelines with the threshold for a positive result set at 10% tumour cells with a circumferential membranous stain. Here too, the Pathology Department took part successfully in the relevant external quality assurance tests (QuIP®). The Her2/neu scoring was performed following the current ASCO/CAP-guidelines in accordance with the recently published recommendations [21].

The Ki-67 stain (clone MIB-1, DAKO) was also carried out in a standardized fashion according to protocol. The percentage of tumour cells with immunohistochemical evidence of MIB-1 protein expression was stated as the Ki-67 proliferation index. Here too there had been successful participation in the relevant external quality assurance test (QuIP®).

For 25 carcinomas with primarily surgical treatment (all of no special type NST, G2, Elston-Ellis grading), a sample of native tumour tissue was collected to determine the concentrations of uPA and PAI-1. Because the information from this laboratory test was only relevant for G2 tumors without nodal metastasis in the clinical routine, no carcinomas of other grade or stage (G1 or G3, lymphonodal metastasized) were includable in this study. From the surgical specimen a sample of frozen tissue was promptly sent to Limbach Laboratory, D-69126 Heidelberg, for an ELISA test. This procedure requires a certain minimum size of tumour (at least 1.3 cm diameter), because on the one hand a tissue sample of around 0.125 cm³ is required for ELISA testing and on the other hand enough material must be retained to guarantee a complete histopathological analysis despite the removal of tumour tissue. The cut-off value for uPA concentrations which are associated with an increased risk of relapse is ≥3 ng/mg total protein, and that for PAI-1 is ≥14 ng/mg total protein. The results of the external test were available after 5 days on average.

OncotypeDX® testing was also arranged in these cases. For this purpose, a paraﬃn block containing tumour tissue from the routine appraisal of the surgical specimen was dispatched; the tissue had previously been ﬁxed in 4% buffered formalin. The shipment took place via a speciﬁed logistics service provider to a central pathology laboratory (Optipath®) in D-60487 Frankfurt/Main chosen by the provider of the test. From there shipping to the central laboratory in the USA and the reporting back of the test results was organised. On average, the result was available 8 days after the sample was sent.

The analysis was statistically descriptive. Because most of the evaluated cases showed identical including criteria (G2, N0) no multivariate analysis was performed. The nuclear grade (intermediate or high) and the mitotic count (without exception low) were also highly similar in the 25 cases, so that we found no indication for a separate analysis.

### Results

For 25 tumours (only luminal-type carcinomas, hormone receptor positive, Her2/neu-negative, G2, pT1 or pT2, not or only minimally nodal metastasized, max. pN1a), the concentrations of uPA and PAI-1 were determined and in addition a multigene test OncotypeDX® was performed. The data for this collective is shown in Table 1.

The protein levels of uPA/PAI-1 and the numerical recurrence score (RS) from the multigene test in the groups with the other histopathological parameters (pT1, pT2, lymphatic invasion, and proliferation Ki67 < 14% or Ki67 > 14%) are presented in Table 2.

No reliable deduction of the results to be expected from additional molecular tests could be made from the conventional parameters tumour stage or lymphatic invasion. For example, pT2 carcinomas showed a substantially lower RS than pT1 carcinomas. The uPA/PAI-1 protein levels tended to be higher with pT1 tumours when compared to pT2 tumours. Factors such as tumour diameter and age at onset did not correlate with any other of the other parameters (values between r = −0.09 and r = −0.13).

The proliferation index (Ki67 < 14% and > 14%) and RS showed an interdependency. Here on average a low risk RS was found with Ki67 < 14% and an intermediate RS

### Table 1 Data of the cohort

| Age          | average 52; median 50 (28–71) |
|--------------|--------------------------------|
| pT1          | n = 12                         |
| pT2          | n = 13                         |
| Diameter of tumor | average 2.1 cm; median 2.0 (1.1–5.0) |
| pN0          | n = 23                         |
| pN1a         | n = 2 (1/6sn) and (2/24), metastases with max. 0.5 cm diameter |
| L0           | n = 15                         |
| L1           | n = 10                         |
| V0           | n = 25                         |
| G2           | n = 25                         |
| Hormone receptors for estrogen and/or progesterone | n = 25 positive |
| Her2/neu     | n = 25 negative (Score 0: n = 6, Score 1+: n = 18, Score 2 + with negative result in FISH: n = 1) |
With Ki67 > 14% (Table 2). For individual values of uPA or PAI-1 there were no differences in the groups with lower and higher proliferation. In comparison of breast carcinomas with regular values of uPA and PAI-1 to carcinomas with an increase of uPA and/or PAI-1, an average and median RS was observed which already indicates an intermediate risk for a tumour relapse in 10 years (RS > 18). The differences were significant when compared with the group with Ki67 < 14% and non-increased uPA/PAI-1 (p < 0.03, Student’s t-test).

Without taking into account proliferative activity, an intermediate risk of a tumour relapse (RS > 18) was even then to be observed when both uPA and PAI-1 are increased. If, however, only one of the two parameters was increased, the RS was below the numerical value of 18 as in cases with non-increased uPA/PAI-1 (Fig. 3), p = 0.093, Student’s t-test.

With an isolated increase of PAI-1 a trend towards a more frequent high rate of proliferation (Ki67 > 14%) could be observed (Fig. 4).

### Discussion

In this pilot study on a small collection of 25 patients from routine diagnostics, a complete set of tumour biology data, including a protein assay of uPA and PAI-1 and a multigene test (OncotypeDX®), was analysed. A primary expansion of the sample of patients was not achievable from the available resources, but even from the recent results valuable information could be obtained for a more comprehensive study to be planned in the future.

The study showed that with the help of a combination of the values of Ki67 and uPA/PAI-1 the general trend of the recurrence score (RS) to be expected from the

### Table 2

| Protein Assay | Average Median +/− deviation |
|---------------|-------------------------------|
| uPA pT1 (ng/ml) | 4.5 3.6 2.5 |
| uPA pT2 (ng/ml) | 2.4 2.4 1.7 |
| PAI-1 pT1 (ng/ml) | 20.8 17.0 11.5 |
| PAI-1 pT2 (ng/ml) | 18.4 15.0 11.5 |
| RS pT1 | 19.1 17.0 8.7 |
| RS pT2 | 13.1 11.0 6.5 |
| uPA L0 (ng/ml) | 3.4 2.9 2.8 |
| uPA L1 (ng/ml) | 3.6 3.1 1.7 |
| PAI-1 L0 (ng/ml) | 22.0 20.0 11.8 |
| PAI-1 L1 (ng/ml) | 15.3 11.0 9.5 |
| RS L0 | 16.9 16.0 9.2 |
| RS L1 | 14.6 14.0 6.2 |
| uPA Ki < 14 (ng/ml) | 3.2 3.5 2.0 |
| uPA Ki > 14 (ng/ml) | 3.6 2.8 3.0 |
| PAI-1 Ki < 14 (ng/ml) | 18.9 17.0 11.2 |
| PAI-1 Ki > 14 (ng/ml) | 20.9 16.0 12.1 |
| RS Ki < 14 | 14.5 13.0 5.7 |
| RS Ki > 14 | 18.1 16.0 11.4 |

**RS recurrence score, L0/L1 - without/with lymphangioinvasion**

In a Spearman ranking correlation of the variables Ki67, uPA/PAI-1 PAI-1 and RS OncotypeDX® there was a trend towards discernible correlations, presented in Table 3.

The differences in the RS became somewhat clearer in the sub-group analysis taking into account the proliferation index (threshold 14%) and uPA/PAI-1 status (Fig. 2). With a proliferation of Ki67 > 14% and simultaneous elevation of uPA and/or PAI-1, an average and median RS was observed which already indicates an intermediate risk for a tumour relapse in 10 years (RS > 18). The differences were significant when compared with the group with Ki67 < 14% and non-increased uPA/PAI-1 (p < 0.03, Student’s t-test).

Without taking into account proliferative activity, an intermediate risk of a tumour relapse (RS > 18) was even then to be observed when both uPA and PAI-1 are increased. If, however, only one of the two parameters was increased, the RS was below the numerical value of 18 as in cases with non-increased uPA/PAI-1 (Fig. 3), p = 0.093, Student’s t-test.

With an isolated increase of PAI-1 a trend towards a more frequent high rate of proliferation (Ki67 > 14%) could be observed (Fig. 4).
multigene test OncotypeDX® can be estimated. Particularly worth emphasising is the evidence of an already elevated recurrence score into the intermediate risk range if Ki67 was > 14% and the protein level of uPA and PAI-1 were increased, and of a RS consistently in the low risk range if both Ki67 and uPA/PAI-1 were not elevated. From this interaction the conclusion may be drawn that in clinical practice an appropriate analysis of this combination of parameters should be envisaged ahead of the multigene test. On the one hand, there are no doubts about the value of multigene tests. On the other hand, however, the costs for these tests are not assumed by some German health insurance schemes. The increasing cost pressure in routine care necessitates making the decision for a multigene test contingent on additional variables and to omit it if not essential in the case of an appropriate constellation of results (Ki67, uPA and PAI-1 all increased or Ki67 and uPA/PAI-1 all not increased). To our knowledge the interrelationships presented here have not yet been examined in the researchable literature. No indications can be derived from the available data as to whether a particular combination of parameters is also reliably associated with a high-risk recurrence score (e.g. by increasing the threshold of the critical Ki67 index from 14 to 20% or 25%). Therefore a further study with a larger patient cohort should be planned. If the result of the pilot study can be confirmed, cost reduction by a factor of 10 could be achieved (according to verbal price information from involved laboratories) with a more targeted use of the multigene tests.

Links are known to exist between the Ki67 index and the values for uPA/PAI-1. Deluche et al. found lower Ki67 indices with negative uPA/PAI-1 than with increased values, with the threshold between low and high Ki67 being set at 20% [22]. They observed that when both parameters were taken into account in therapy planning, 9% fewer patients were received a recommendation for adjuvant chemotherapy than in cases where only the St. Gallen criteria were used. A qualifying comment to be made is that the ELISA (Enzyme-linked Immunosorbent Assay) for uPA/PAI-1 is only possible on fresh or frozen tumour tissue; ideally, a tumour sample of not less than 0.125 cm³ must be available. The applicability of the procedure is thus limited by size of the tumour, because experience has shown that with tumour diameters of below 1.3 cm not enough tissue can be obtained without jeopardising the routine diagnostic procedures, especially with regard to the distance of the tumour from the resection margin. Although only an ELISA-based uPA/PAI-1 determination has been validated, efforts are being made to develop immunohistochemical assays for formalin-fixed paraffin-embedded tissue. A study has shown that the uPA/PAI values determined by means of immunohistochemical tests correlate significantly with the values of a validated ELISA [23].

The uPA/PAI-1 test is currently no longer recommended in the new version of the German S3 guideline.

### Table 3 Positive correlations between different variables (Spearman correlation)

| Correlation                        | Correlation Coefficient |
|------------------------------------|-------------------------|
| uPA/PAI-1 to RS OncotypeDX®         | 0.525                   |
| uPA/PAI-1 to proliferative index Ki67 | 0.460                   |
| Ki67 to RS OncotypeDX®             | 0.517                   |

*Fig. 2 Average and median recurrence scores (RS) of OncotypeDX® depends from results in immunohistochemical measurement of Ki67-index and protein levels of uPA/PAI-1 (Ki67 < 14% and uPA/PAI-1 regular to Ki67 > 14% and uPA/PAI-1 elevated p < 0.03)*
on breast cancer of 2017. The reason for this was the insufficient data situation for a prognostic assessment, because although the patients included in the older studies were given chemotherapy in the case of increased values, but no anti-hormonal therapy was administered when the values were not increased, so that no direct comparison of the prognosis of the two sample groups could be guaranteed on the basis of present therapeutic standards [24]. Furthermore, the Her2/neu status of the tumours was not known in previous studies. With regard to all breast carcinomas, however, there are indications that a link exists between uPA/PAI-1 and the known intrinsic subtypes. HER2-positive or triple negative carcinomas are much more rarely uPA/PAI-1-negative than luminal-A type carcinomas [25].

According to the guidelines of the American Society of Clinical Oncology (ASCO), the levels of uPA and PAI-1 can be drawn upon for the decision for or against adjuvant chemotherapy; this is not recommended for Ki67 alone [26]. The analysis of uPA/PAI-1 can thus usefully supplement the information gained from conventional clinical-pathological parameters in the decision for or against adjuvant chemotherapy in cases of hormone-receptor-positive, Her2/neu-negative breast carcinomas [27], even before a multigene test has to be arranged. A
further aspect is the difference in cost which can be seen as an additional argument in favour of uPA/PAI-1 testing. While this ELISA test tends to cost from 200 to 300 € (in Germany), the multigene array is much more expensive with around 4000 UROS. If the uPA/PAI-1/Ki67 constellation points to low or higher risk this can be avoided in selected cases.

However, no conclusions concerning the success of chemotherapy may be drawn solely from increased values [28]. The risk stratification and therapy planning for a breast carcinoma never take place on the basis of an isolated parameter, not even if a multigene test is available, therefore the above assessment is not problematic.

Conclusions
The protein-based measurement of uPA/PAI from frozen tumour tissue and additional multigene tests enable a more differentiated risk assessment of the biological tumour behaviour than the sole evaluation of conventional criteria. The decision as to which test procedure is to be used can be made based on the evidence of clinical and methodical validation. In the overall context of the individual disease, extended analyses on tumour tissue must be critically weighed up in view of the benefit to be expected against the arising costs.

Acknowledgements
Acknowledgement to the technical staff of Pathology of Leopoldina Hospital Schweinfurt.

Funding
This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to local regulations but are available from the corresponding author on reasonable request.

Authors’ contributions
HUV created the concept and execution of this study, MW interpreted the clinical characteristics of tumours. HUV and LF were major contributors in analysing and preparing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Ethical approval was obtained by the Ethics Commission of the Medical Faculty of the University of Wuerzburg (Versbacher Str. 9, D-97078 Wuerzburg), documented in correspondence no. 2010/2013/01. In accordance with the Declaration of Helsinki, the scientific study of the cross-sectional study results is performed with completely and irreversibly anonymised personal patient data (name, date of birth, address, etc.) Further consent to participate was given by the legal regulations by BayKRG Art. 27 from 1.1.2012. We have adhered strictly to these guidelines.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Pathology, Leopoldina Krankenhaus GmbH, Gustav-Adolf-Str 8, D-97422 Schweinfurt, Germany. 2Department of Gynecology, Leopoldina Krankenhaus GmbH, Gustav-Adolf-Str 8, D-97422 Schweinfurt, Germany.

Received: 21 June 2018 Accepted: 14 August 2018
Published online: 31 August 2018

References
1. Lampelli M, Arko D, Cis-Sikosek N, Kavalar R, Ravnik M, Jeresek-Novakovic B, Dobnik S, Divvnik NF, Takac I. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors. Radiol Oncol. 2015;49(4):357–64.
2. Binder BR, Mihalj J. The plasminogen activator inhibitor “paradox” in cancer. Immunol Lett. 2008;118(2):116–24.
3. Hildenbrand R, Schaaf A. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol. 2009;34(1):15–23.
4. Andreassen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57(1):25–40.
5. Chen Y, Kelm JR Jr, Budd RC, Sobel BE, Schneider DJ. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem. 2004;92(1):178–88.
6. Ulisse S, Baldini E, Sorrenti S, D’Armierno M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9(1):32–71.
7. Preisser K, Karre SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol. 2000;12(5):621–8.
8. Rosenberg S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective. Curr Pharm Des. 2003;9(19):4.
9. Reuning U, Magdonl,V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol. 1998;13(5):893–906.
10. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fenió M, Eppenberger-Castori S, Sweep CG, ULM K, Peyrat JP, Martin PM, Magdonl H, Brünn C, Duggan C, Lisboa BW, BendaHL PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Davenhiller G, Windbichler G, Cufer T, Borstman S, Kung W, Beex LV, Klijn JG, O’Higgins N, Eppenberger UJ, Jänicke F, Smitt M, Foekens IA. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94(2):116–28.
11. Jänicke F, Schmitt M, Pache L, ULM K, Harbeck N, Hoffer G, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24(3):195–208.
12. Rabl Z, Todorovic-Rakov G, Vujasinovic T, Milovanovic J, Nikolic-Vukosavljevic D. Markers of progression and invasion in short term follow up of untreated breast cancer patients. Cancer Biomark. 2015;15(6):745–54.
13. De Cremond P, Grandin L, Dieras V, Savignoni A, Degeorge A, Salmon R, Bollet MA, Reyel F, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X, Bollet MA, Reyal F, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X, Völker et al. Diagnostic Pathology (2018) 13:67
16. Carlson JJ, Roth JA. The impact of the Oncotype DX breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;141(1):13–22.

17. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shah S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martin S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063–71.

18. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugatini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd LR, Yeh IT, Yoshizawa C, Alired DC, Osborne CK, Hayes DF, Breast Cancer intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.

19. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28(10):1677–83.

20. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.

21. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spear PA, Vance GH, Viale G, McShane LM, Dowsett M. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018; https://doi.org/10.5858/arpa.2018-0902-SA.

22. Deluche E, Venat-Bouvet L, Leobon S, Fermeaux V, Mollard J, Saidi N, Jammet I, Aubard Y, Tubiana-Mathieu N. Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers. BMC Cancer. 2017;17(1):662.

23. Lang DS, Heilenkotter U, Mollerus A, Behrens O, Vollmer E, Goldmann T. Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer. Breast. 2013;22(5):736–43.

24. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C. ChemOno-D0 Study Group. Ten-year analysis of the prospective multicentre chemOno trial validates American Society of Clinical Oncology (ASCO)- recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013;49(8):1825–35.

25. Wittel I, Milde-Langosch K, Schmidt M, Kasch T, Becker S, Wirtz R, Vöhringer S, Schütze D, Jänicke F, Müller V. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco Targets Ther. 2014;7(7):2205–13.

26. Harris LN, Ismaila N, McShane LM, Andre F, Collar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF, American Society of Clinical Oncology. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134–50.

27. Boga K, Džodić R, Djurišić I, Marković I, Vujasinović T, Markićević M, Nikolić-Vukosavljević D. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumours with ER/PR expression, during an early follow-up. Tumor Biol 2015; 36:8193–2000.

28. Bellocco JP, Luporsi E, Barrière J, Bonastre J, Chrettrit J, Le Coroller AG, de Crémoix P, Fina F, Gauchez AS, Kassab-Chahinh D, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdini L, Mazeau-Woynar V. uPA/PAI-1, Oncotype DX®, MammaPrint®. Prognosis and predictive values for clinical utility in breast cancer management. Ann Pathol. 2014;34(5):349–51.